These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 26598753)

  • 1. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial Differences in Utilization of Breast Conservation Surgery: Results from the National Cancer Data Base (NCDB).
    Thomas P; Killelea BK; Horowitz N; Chagpar AB; Lannin DR
    Ann Surg Oncol; 2016 Oct; 23(10):3272-83. PubMed ID: 27503494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative.
    Livaudais JC; Lacroix A; Chlebowski RT; Li CI; Habel LA; Simon MS; Thompson B; Erwin DO; Hubbell FA; Coronado GD
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):365-73. PubMed ID: 23275187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
    Woriax HE; Thomas SM; Plichta JK; Rosenberger LH; Botty van den Bruele A; Chiba A; Hwang ES; DiNome ML
    J Clin Oncol; 2024 May; 42(14):1635-1645. PubMed ID: 38394476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
    Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
    JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
    Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
    J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
    Chen L; Li CI
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
    Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
    J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
    Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
    Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.
    Hausauer AK; Keegan TH; Chang ET; Clarke CA
    Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
    Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
    Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
    Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.